Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
Cancers · 23.02.2023 · 15 (5) · 1413
DOI: 10.3390/cancers15051413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.02.2023. Verfasst von Katrin Almstedt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We examined differences in HER2 expression between primary tumors and distant metastases, particularly within the HER2-negative primary breast cancer cohort (HER2-low and HER2-zero). The retrospective study included 191 consecutive paired samples of primary breast cancer and distant metastases diagnosed between 1995 and 2019. HER2-negative samples were divided into HER2-zero (immunohistochemistry [IHC] score 0) and HER2-low (IHC score 1+ or 2+/in situ hybridization [ISH]-negative). The main objective was to analyze the discordance rate between matched primary and metastatic samples, focusing on the site of distant metastasis, molecular subtype, and de novo metastatic breast cancer. The relationship was determined by cross-tabulation and calculation of Cohen′s Kappa coefficient. The final study cohort included 148 paired samples. The largest proportion in the HER2-negative cohort was HER2-low [primary tumor 61.4% (n = 78), metastatic samples 73.5% (n = 86)]. The discordance rate between the HER2 status of primary tumors and corresponding distant metastases was 49.6% (n = 63) (Kappa −0.003, 95%CI −0.15–0.15). Development of a HER2-low phenotype occurred most frequently (n = 52, 40.9%), mostly with a switch from HER2-zero to HER2-low (n = 34, 26.8%). Relevant HER2 discordance rates were observed between different metastatic sites and molecular subtypes. Primary metastatic breast cancer had a significantly lower HER2 discordance rate than secondary metastatic breast cancer [30.2% (Kappa 0.48, 95%CI 0.27–0.69) versus 50.5% (Kappa 0.14, 95% CI −0.03–0.32)]. This highlights the importance of evaluating potentially therapy-relevant discordance rates between a primary tumor and corresponding distant metastases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University Medical Center Mainz, 55131 Mainz, Germany.
- Department of Statistics, TU Dortmund University, 44227 Dortmund, Germany.
- Institute of Pathology, University Medical Center Mainz, 55131 Mainz, Germany.
- Leibniz-Research Centre for Working Environment and Human Factors at the TU Dortmund (IfADo), 44139 Dortmund, Germany.
ORCID-Profile: Lisa Krauthauser, Franziska Kappenberg, Roxana Schwab, Marcus Schmidt
Zitieren
APA
Almstedt, K., Krauthauser, L., Kappenberg, F., Wagner, D. C., Heimes, A. S., Battista, M. J., Anic, K., Krajnak, S., Lebrecht, A., Schwab, R., Brenner, W., Weikel, W., Rahnenführer, J., Hengstler, J. G., Roth, W., Hasenburg, A., Stewen, K., & Schmidt, M. (2023). Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. Cancers, 15(5), 1413. https://doi.org/10.3390/cancers15051413
Vancouver
Almstedt K, Krauthauser L, Kappenberg F, Wagner DC, Heimes AS, Battista MJ, et al. Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. Cancers. 2023;15(5):1413. doi:10.3390/cancers15051413
BibTeX
@article{Almstedt2023,
author = {Almstedt, Katrin and Krauthauser, Lisa and Kappenberg, Franziska and Wagner, Daniel-Christoph and Heimes, Anne-Sophie and Battista, Marco J and Anic, Katharina and Krajnak, Slavomir and Lebrecht, Antje and Schwab, Roxana and Brenner, Walburgis and Weikel, Wolfgang and Rahnenführer, Jörg and Hengstler, Jan G and Roth, Wilfried and Hasenburg, Annette and Stewen, Kathrin and Schmidt, Marcus},
title = {Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {5},
pages = {1413},
doi = {10.3390/cancers15051413}
}
EUVIMED